PCM
TVRD

Penserra Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Penserra Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,764
Closed -$19K – 1221
2024
Q3 		$19K Sell
1,764
-127
-7% -$1.49K ﹤0.01% 869
2024
Q2 		$18K Buy
1,891
+70
+4% +$1.67K ﹤0.01% 914
2024
Q1 		$59K Sell
1,821
-444
-20% -$11.5K ﹤0.01% 867
2023
Q4 		$60K Hold
2,265
– – ﹤0.01% 973
2023
Q3 		$136K Sell
2,265
-2,222
-50% -$208K ﹤0.01% 832
2023
Q2 		$457K Buy
4,487
+34
+0.8% +$4.68K 0.01% 554
2023
Q1 		$787K Sell
4,453
-449
-9% -$150K 0.02% 425
2022
Q4 		$1.9M Buy
4,902
+77
+2% +$29.2K 0.04% 362
2022
Q3 		$1.63M Sell
4,825
-694
-13% -$251K 0.05% 297
2022
Q2 		$1.81M Buy
5,519
+267
+5% +$93.7K 0.05% 306
2022
Q1 		$2.3M Sell
5,252
-45
-0.8% -$18.5K 0.05% 319
2021
Q4 		$2.32M Sell
5,297
-78
-1% -$39.2K 0.05% 345
2021
Q3 		$2.99M Sell
5,375
-1,538
-22% -$772K 0.06% 298
2021
Q2 		$3.55M Sell
6,913
-1,746
-20% -$1.11M 0.06% 294
2021
Q1 		$6.77M Buy
8,659
+5,487
+173% +$3.76M 0.13% 190
2020
Q4 		$1.73M Buy
3,172
+1,341
+73% +$703K 0.04% 271
2020
Q3 		$837K Sell
1,831
-1
-0.1% -$581 0.03% 282
2020
Q2 		$1.13M Buy
1,832
+270
+17% +$149K 0.06% 237
2020
Q1 		$741K Buy
1,562
+1,302
+501% +$708K 0.05% 314
2019
Q4 		$152K Sell
260
-14
-5% -$9.82K 0.01% 506
2019
Q3 		$180K Buy
+274
New +$228K 0.02% 408

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Penserra Capital Management's TVRD Position: Q4 2024 in Review

Penserra Capital Management sold out of Tvardi Therapeutics (TVRD) in Q4 2024, closing a stake of 1,764 shares — an estimated $19K sold.

Penserra Capital Management first reported a position in TVRD in Q3 2019 and held it in 21 quarters. The position peaked at $6.77M in Q1 2021. 43 funds tracked by Wall St. Rank hold TVRD as of Q4 2024.

  • Penserra Capital Management reported no remaining Tvardi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Penserra Capital Management sold 1,764 Tvardi Therapeutics shares in Q4 2024, an estimated $19K.
  • Penserra Capital Management first reported a position in Tvardi Therapeutics in Q3 2019 and held it in 21 quarters.
  • Penserra Capital Management's Tvardi Therapeutics position peaked at $6.77M in Q1 2021.
  • 43 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2024.

Based on Penserra Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.